沈迈注射改善了心肌梗塞后心力衰竭中的脂质代谢,基于网络药理学和实验验证的实验验证
Heliyon
|November 11, 2024
概括
沈迈注射可以通过增强脂质代谢来改善心肌梗塞后的心脏功能. 它调节PPARα/SIRT1/PGC1α通路,减少炎症和纤维化.
科学领域:
- 心血管研究研究心血管研究
- 传统中国医药 传统中国医药
- 分子药理学分子药理学
背景情况:
- 沈迈注射 (SMI) 是一种传统的中医药,用于治疗心血管疾病.
- 这项研究研究了SMI对心肌梗塞后心力衰竭 (pMIHF) 的脂质代谢的影响.
研究的目的:
- 阐明SMI在pMIHF中影响脂质代谢的机制.
- 用体内和体外模型验证预测的目标和途径.
主要方法:
- 网络药理学确定了SMI的活性成分,标和途径.
- 一个pMIHF小鼠模型和一个缺血/再输血 (I/R) 细胞模型被用于验证.
- 分子对接评估了SMI组件和PPARα之间的结合亲和力.
主要成果:
- 网络药理学确定了26个核心目标,包括PPARα和SIRT1,并预测了PPARα通路.
- 在pMIHF小鼠中,SMI改善了心脏功能,减少了脂质异常,炎症和纤维化.
- 在I/R细胞中,SMI降低了亡和炎症标志物,同时提高了PPARα,SIRT1和PGC1α的调节.
结论:
- 通过增强心肌脂代谢,SMI可以改善pMIHF.
- 该机制涉及PPARα/SIRT1/PGC1α通路的上调.
- SMI在涉及脂质代谢功能障碍的心血管疾病中显示出治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
456
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
456